Evidence map›Paper›PMID 34817835›Full record

Observational studyJournal of nephrology2022

Effect of emergency start and central venous catheter on outcomes in incident hemodialysis patients: a prospective observational cohort.

Ulviyya Alizada, Erik-André Sauleau, Thierry Krummel, Olivier Moranne, Isabelle Kazes, Cécile Couchoud, Thierry Hannedouche, the REIN registry

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Transitions between dialysis modalities.Journal of nephrology · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Ulviyya AlizadaPublic Health Departments, Group Methods in Clinical Research, University Hospital of Strasbourg, Strasbourg, France.
Erik-André SauleauPublic Health Departments, Group Methods in Clinical Research, University Hospital of Strasbourg, Strasbourg, France.
Thierry KrummelDepartment of Nephrology, University Hospital of Strasbourg, Strasbourg, France.
Olivier MoranneDepartment of Nephrology, University Hospital of Nimes, Nimes, France.
Isabelle KazesDepartment of Nephrology, Regional Coordination of Champagne-Ardenne for Rein Registry, University Hospital of Reims, Reims, France.
Cécile CouchoudAgency of Biomedicine, National Coordination REIN Registry, Paris, France.
Thierry HannedoucheSchool of Medicine, University of Strasbourg, Strasbourg, France. thannedouche@unistra.fr.ORCID 0000-0002-8493-8260
the REIN registry
EM Strasbourg Business School · FRAgence de la Biomédecine · FRCentre Hospitalier Universitaire de Nîmes · FRCentre Hospitalier Universitaire de Reims · FRHôpital Civil, Strasbourg · FRInstitut de Recherche contre les Cancers de l’Appareil Digestif · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnfavorable conditions at hemodialysis inception reduce the survival rate. However, the relative contribution to outcomes of predialysis follow-up, symptoms, emergency start or central venous catheter (CVC) is unknown.

methodsWe analyzed the determinants of survival according to dialysis initiation conditions in the nationwide REIN registry, using two methods based either on clinical classification or data mining. We divided patients into four groups according to dialysis initiation (emergency vs planned, symptoms or not, previous follow-up). "Followed planned starters" began dialysis as outpatients and with an arteriovenous fistula (AVF). "Followed symptomatic non-urgent starters" were patients who started earlier because of any non-urgent symptomatic event. "Followed urgent starters" had seen a nephrologist before inception but started dialysis in an emergency condition. "Unknown urgent starters" were patients without any follow-up and who had a CVC at inception.

results"Followed urgent" starters had the lowest 2-year survival rate (66.8%) compared to "followed planned" (77.3%), "followed symptomatic non urgent" (79.2%), and "unknown urgent" (71.7%). Compared to other groups, the risk of mortality was lower in followed symptomatic non urgent (HR 0.86 95% CI 0.75-0.99) and higher in followed urgent starters (HR 1.05 (95% CI 0.94-1.18). In data mining Classification And Regression Tree regrouping in five categories, the lowest 2-year survival (52.3%) was in over 70-year-old starters with a CVC. The survival was 93.2% in under 57-year-old patients without active cancer, 82.5% in 57-70-year-old individuals without cancer, 72.4% in over 70-year-old patients without CVC and 61.4% in under 70-year-old subjects with cancer. The hazard ratio of data mining categories varied between 2.12 (95% CI 1.73-2.60) in 57-70-year-old subjects without cancer and 4.42 (95% CI 3.64-5.37) in over 70-year-old patients with CVC. Therefore, regrouping incident patients into five data mining categories, identified by age, cancer, and CVC use, could discriminate the 2-year survival in patients starting hemodialysis.

conclusionsAlthough each classification captured different prognosis information, both analyses showed that starting hemodialysis on a CVC has more dramatic outcomes than emergency start per se.

Indexed as

Arteriovenous Shunt, SurgicalCentral Venous CathetersKidney Failure, ChronicAgedCohort StudiesHumansMiddle AgedNephrologistsRenal DialysisSurvival RateChronic hemodialysisEpidemiology, Data miningSurvival

Identifiers

PMID34817835
OpenAlexW3216995823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.